Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTAVE: Enadenotucirev in Platinum-Resistant Ovarian Cancer
NCT02028117Phase 1Completed
- Sponsor
- Akamis Bio
- Start
- Jun 2014
- Primary completion
- Nov 2019
- Modality
- Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 1, open-label trial of enadenotucirev in epithelial ovarian cancer (EOC) (2 arms), sponsored by Akamis Bio. Primary endpoints: Maximum Tolerated Dose and Progression-Free Survival. Started Jun 2014; status: completed.
02
Drugs
enadenotucirev
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT02028117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02028117.